Novel Surveillance

One aim of the new NDEWS is to incorporate and leverage novel surveillance methods to ensure the early detection of signals of new and emerging drug trends.

While lagged indicators such as overdose deaths, drug seizures, and treatment admissions are useful for longer-term monitoring of patterns of drug use and associated consequences, these indicators are unable to detect potentially dangerous trends as they emerge, before serious consequences and death.

To identify early signals of shifts in drug use trends and the onset of drug epidemics, real-time, ongoing surveillance is required. This form of national monitoring is the goal of NDEWS, which will be accomplished by synthesizing traditional, lagged sources of data with novel, leading sources, and the development of an innovative machine learning approach to detect the emergence of new psychoactive substances in real-time through algorithms deployed to darknet drug markets and forums.

NDEWS is funded by the National Institute on Drug Abuse to the University of Florida (MPI: Cottler (contact), Co-Is: Goldberger, Nixon, Striley), NYU Langone Health (MPI: Palamar), and Florida Atlantic University (Co-I: Barenholtz)

NDEWS briefings, reports, and figures may be shared, reproduced, or excerpted, provided NDEWS is appropriately attributed, and a link to the original source material is included. NDEWS materials must not be sensationalized with language or imagery. Reference must be made to the most current version of the original NDEWS source material so as not to disseminate outdated or inaccurate information. NDEWS does not endorse or assume responsibility for third-party interpretation, commentary, or AI-generated content, including images, which use or reference NDEWS materials.